US biotech firm Moderna said that trials had shown its COVID-19 vaccine is “highly effective” in adolescents aged 12 to 17 and the company would seek regulators’ approval in June.
Moderna’s CEO said, “We are encouraged that mRNA-1273 was highly effective at preventing the coronavirus disease in adolescents. We will submit these results to the US FDA and regulators globally in early June and request authorization.”
If greenlit, as expected, it would be the second coronavirus vaccine authorized for use in US adolescents after Pfizer’s, which began rolling out this month for 12-to-15-year-olds.
The Moderna study enrolled 3,732 adolescents aged 12 to 17 and randomized, with two-thirds receiving the two doses of the vaccine and the rest receiving a placebo.
After two doses, no cases of symptomatic COVID-19 were observed in the vaccine group compared to four cases in the placebo group, meaning the shots were 100 percent effective.